Unichem gets USFDA nod for hypertension treatment tablets
NEW DELHI: Drug firm Unichem Laboratories has received approval from the US health regulator for its Losartan Potassium tablets used in treatment of hypertension.
"The company has received ANDA approval from the United States Food and Drug Administration (US FDA) for Losartan Potassium tablets USP," Unichem Laboratories said in a filing to BSE.
The product will be commercialised from the company's Ghaziabad plant, it added.
The product is generic version of Merck Sharp & Dohme Corp's Cozaar tablets in the strength of 25 mg, 50 mg and 100 mg, Unichem said.
Losartan Potassium is used for treatment of hypertension, it added.
"The company has received ANDA approval from the United States Food and Drug Administration (US FDA) for Losartan Potassium tablets USP," Unichem Laboratories said in a filing to BSE.
The product will be commercialised from the company's Ghaziabad plant, it added.
The product is generic version of Merck Sharp & Dohme Corp's Cozaar tablets in the strength of 25 mg, 50 mg and 100 mg, Unichem said.
Losartan Potassium is used for treatment of hypertension, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.